
|Videos|June 16, 2017
Comprehensive Genomic Profiling With Loss of Heterozygosity for Ovarian Cancer Treatment
Author(s)Julia Elvin, MD, PhD
Julia Elvin, MD, PhD, vice president and senior associate medical director, Foundation Medicine, discusses a study of comprehensive genomic profiling with loss of heterozygosity to identify therapeutically relevant subsets of ovarian cancer.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Aromatase Inhibitors Favored as Adjuvant ET in HR+/HER2+ Early Breast Cancer
2
ASCENT-07: Sacituzumab PFS Not Significant vs Chemo in HR+/HER2- BC
3
Off-the-Shelf In Vivo BCMA CAR T KLN-1010 Yields Deep R/R Myeloma Responses
4
Giredestrant Improves IDFS vs SOC in ER+/HER2– Early Breast Cancer
5










































